Ahmad Tarek A, Haroun Medhat, Hussein Ahmad A, El Ashry El Sayed H, El-Sayed Laila H
Department of Biotechnology, Institute of Graduate Studies and Research, Alexandria University;
Department of Chemistry, Faculty of Science, Alexandria University;
Infect Dis Rep. 2012 Jul 23;4(2):e33. doi: 10.4081/idr.2012.e33. eCollection 2012 Apr 27.
Klebsiella pneumoniae is a major cause of nosocomial pneumonia, septicemia and urinary tract infections, especially in newborns, blood cancer patients, and other immunocompromised candidates. The control of K. pneumoniae is a complicated issue due to its tight pathogenesis. Immuno-prophylactic preparations, especially those directed toward the bacterium O-antigen, showed to be the most successful way to prevent the infection incidence. However, all previously proposed preparations were either of limited spectrum or non-maternal, and hence not targeting the main Klebsiella patients. Moreover, all preparations were directed only to prevent the respiratory diseases due to that pathogen. This article addresses the development of a method originally used to purify the non-capsular bacterial-endotoxins, as a new and easy method for vaccine production against K. pneumoniae. The application of this method was preceded by a biotechnological control of capsular polysaccharide production in K. pneumoniae. The new produced natural conjugate between the bacterial O-antigen and its outer membrane proteins was evaluated by physicochemical and immunological methods to investigate its purity, integrity, safety and immunogenicity. It showed to be pure, stable, safe for use, and able to elicit a protective immunoglobulin titer against different Klebsiella infections. This immune-response proved to be transferable to the offspring of the vaccinated experimental rabbits via placenta.
肺炎克雷伯菌是医院获得性肺炎、败血症和尿路感染的主要病因，尤其在新生儿、血癌患者及其他免疫功能低下者中。由于其发病机制复杂，肺炎克雷伯菌的控制是一个复杂的问题。免疫预防制剂，特别是针对细菌O抗原的制剂，被证明是预防感染发生的最成功方法。然而，所有先前提出的制剂要么谱效有限，要么非母体来源，因此未针对主要的肺炎克雷伯菌感染患者。此外，所有制剂仅针对预防该病原体引起的呼吸道疾病。本文介绍了一种最初用于纯化非荚膜细菌内毒素的方法的开发，作为一种针对肺炎克雷伯菌的新型简易疫苗生产方法。在应用该方法之前，对肺炎克雷伯菌的荚膜多糖生产进行了生物技术控制。通过物理化学和免疫学方法对新产生的细菌O抗原与其外膜蛋白之间的天然缀合物进行了评估，以研究其纯度、完整性、安全性和免疫原性。结果表明，它纯净、稳定、使用安全，能够引发针对不同肺炎克雷伯菌感染的保护性免疫球蛋白滴度。这种免疫反应被证明可以通过胎盘传递给接种疫苗的实验兔的后代。
